Related Experiment Video
Updated: Jul 13, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
Coronary microvascular dysfunction in the setting of chronic ischemia is independent of arginase activity
Neel R Sodha1, Munir Boodhwani, Richard T Clements
1Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Insights
Chronic myocardial ischemia causes coronary microvascular dysfunction independently of Arginase I. This suggests alternative therapeutic strategies beyond arginine may be needed to treat this condition.
Area of Science:
- Cardiovascular Research
- Endothelial Function
- Myocardial Ischemia
Background:
- Chronic myocardial ischemia impairs coronary microcirculation and endothelial function, affecting nitric oxide signaling and tissue perfusion.
- Endothelial dysfunction is linked to impaired angiogenesis and may involve reduced l-arginine bioavailability.
- This study investigated the role of Arginase I activity in chronic myocardial ischemia-induced endothelial dysfunction.
Purpose of the Study:
- To determine if chronic myocardial ischemia increases Arginase I activity, thereby reducing l-arginine availability.
- To assess the impact of Arginase I on coronary microvascular function in an ischemic heart model.
Main Methods:
- Chronic myocardial ischemia was induced in Yucatan miniswine for 7 weeks using an ameroid constrictor.
- Arginase I expression, activity, and eNOS phosphorylation were analyzed in ischemic and non-ischemic tissues.
- Coronary microvascular relaxation studies were conducted to evaluate endothelial-dependent and independent responses.
Main Results:
- Arginase I expression and activity were not significantly different between ischemic and non-ischemic territories.
- Coronary microvessels from the ischemic territory showed impaired endothelial-dependent relaxation.
- No significant correlation was found between arginase activity and the degree of microvascular vasorelaxation.
Conclusions:
- Coronary microvascular dysfunction in chronic myocardial ischemia is independent of Arginase I.
- Therapeutic strategies targeting arginine bioavailability may not be effective for this condition.
- Alternative approaches are needed to address ischemia-induced endothelial dysfunction.
Background:
Chronic myocardial ischemia induces endothelial dysfunction in the coronary microcirculation resulting in impaired nitric oxide signaling. This dysfunction has wide-ranging effects including impaired tissue perfusion and is implicated in impairment of the angiogenic process in settings of endothelial dysfunction. We hypothesized chronic myocardial ischemia results in increased activity of Arginase I, diminishing bioavailability of l-arginine, the substrate for endothelial nitric oxide production.
Methods:
Chronic myocardial ischemia was induced for 7-weeks in 6 Yucatan miniswine utilizing an ameroid constrictor placed around the left circumflex coronary artery. Ischemic and non-ischemic tissue was harvested at the 7-week time point. Expression of Arginase I, eNOS, and phospho-eNOS was assessed utilizing Western blotting. Arginase activity was measured. Immunofluorescent staining assessed expression of Arginase I between ischemic and non-ischemic microvessels. Coronary microvascular relaxation studies were performed.
Results:
Arginase I expression, activity, and staining was similar between ischemic and non-ischemic territories. Significant impairments in coronary microvascular relaxation were observed in microvessels from the ischemic territory in response to endothelial-dependent agents but remained similar between territories in response to endothelial independent agents. Regression analysis between arginase activity and degree of microvascular vasorelaxation demonstrated no significant correlation.
Conclusions:
Coronary microvascular dysfunction in the setting of chronic myocardial ischemia occurs independently of Arginase I activity and expression. Alternative therapeutic strategies focusing away from arginine may be need for the treatment of this dysfunction.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease I: Introduction
Angina II: Classification
